Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

BACKGROUND: This prospective, phase II trial evaluated the efficacy and safety of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours (GISTs) after failure of at least imatinib and sunitinib. METHODS: Patients received oral dovitinib, 500 mg once daily, for 5 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Y-K, Yoo, C, Ryoo, B-Y, Lee, J J, Tan, E, Park, I, Park, J H, Choi, Y J, Jo, J, Ryu, J-S, Ryu, M-H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817332/
https://www.ncbi.nlm.nih.gov/pubmed/24084771
http://dx.doi.org/10.1038/bjc.2013.594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817332/
https://www.ncbi.nlm.nih.gov/pubmed/24084771
http://dx.doi.org/10.1038/bjc.2013.594

Ejemplares similares